Rallybio ended the first quarter with nearly $128 million in the bank, and it’s heading to Wall Street for more.
The news comes days after Rallybio established proof of concept for its lead program, RLYB211, in fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare disease that causes a mother’s immune system to attack her fetus or newborn child’s platelets.